These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31680058)

  • 1. Drug Discovery Platform Targeting M. tuberculosis with Human Embryonic Stem Cell-Derived Macrophages.
    Han HW; Seo HH; Jo HY; Han HJ; Falcão VCA; Delorme V; Heo J; Shum D; Choi JH; Lee JM; Lee SH; Heo HR; Hong SH; Park MH; Thimmulappa RK; Kim JH
    Stem Cell Reports; 2019 Dec; 13(6):980-991. PubMed ID: 31680058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Drugs for an Old Foe: Mycobacterium tuberculosis Meets PSC-Derived Macrophages.
    Haake K; Lachmann N
    Stem Cell Reports; 2019 Dec; 13(6):957-959. PubMed ID: 31951563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
    Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P
    Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis.
    Schaaf K; Smith SR; Hayley V; Kutsch O; Sun J
    J Vis Exp; 2017 Mar; (121):. PubMed ID: 28362407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.
    Schaaf K; Hayley V; Speer A; Wolschendorf F; Niederweis M; Kutsch O; Sun J
    Assay Drug Dev Technol; 2016 Aug; 14(6):345-54. PubMed ID: 27327048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening.
    Grzelak EM; Choules MP; Gao W; Cai G; Wan B; Wang Y; McAlpine JB; Cheng J; Jin Y; Lee H; Suh JW; Pauli GF; Franzblau SG; Jaki BU; Cho S
    J Antibiot (Tokyo); 2019 Oct; 72(10):719-728. PubMed ID: 31292530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections.
    Heemskerk MT; Korbee CJ; Esselink JJ; Dos Santos CC; van Veen S; Gordijn IF; Vrieling F; Walburg KV; Engele CG; Dijkman K; Wilson L; Verreck FAW; Ottenhoff THM; Haks MC
    Sci Rep; 2021 Oct; 11(1):19634. PubMed ID: 34608194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput screening of compounds library to identify novel inhibitors against latent Mycobacterium tuberculosis using streptomycin-dependent Mycobacterium tuberculosis 18b strain as a model.
    Sharma S; Bhat R; Singh R; Sharma S; Wazir P; Singh PP; Vishwakarma RA; Khan IA
    Tuberculosis (Edinb); 2020 Sep; 124():101958. PubMed ID: 32791471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Deconstructed Granuloma: A Complex High-Throughput Drug Screening Platform for the Discovery of Host-Directed Therapeutics Against Tuberculosis.
    Huang L; Kushner NL; Theriault ME; Pisu D; Tan S; McNamara CW; Petrassi HM; Russell DG; Brown AC
    Front Cell Infect Microbiol; 2018; 8():275. PubMed ID: 30155446
    [No Abstract]   [Full Text] [Related]  

  • 11. An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis.
    Gupta A; Bhakta S
    J Antimicrob Chemother; 2012 Jun; 67(6):1380-91. PubMed ID: 22398649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.
    Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M
    PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis.
    Zheng X; Av-Gay Y
    J Vis Exp; 2017 Apr; (122):. PubMed ID: 28448028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.
    Ekins S; Freundlich JS; Hobrath JV; Lucile White E; Reynolds RC
    Pharm Res; 2014 Feb; 31(2):414-35. PubMed ID: 24132686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes.
    Howard NC; Marin ND; Ahmed M; Rosa BA; Martin J; Bambouskova M; Sergushichev A; Loginicheva E; Kurepina N; Rangel-Moreno J; Chen L; Kreiswirth BN; Klein RS; Balada-Llasat JM; Torrelles JB; Amarasinghe GK; Mitreva M; Artyomov MN; Hsu FF; Mathema B; Khader SA
    Nat Microbiol; 2018 Oct; 3(10):1099-1108. PubMed ID: 30224802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis.
    Manning AJ; Ovechkina Y; McGillivray A; Flint L; Roberts DM; Parish T
    Methods; 2017 Aug; 127():3-11. PubMed ID: 28366666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.
    Jagadeb M; Rath SN; Sonawane A
    J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysaccharide rich extract (PRE) from Tinospora cordifolia inhibits the intracellular survival of drug resistant strains of Mycobacterium tuberculosis in macrophages by nitric oxide induction.
    Gupta PK; Kulkarni S
    Tuberculosis (Edinb); 2018 Dec; 113():81-90. PubMed ID: 30514517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.